Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×First-generation antipsychotics. Butyrophenone derivatives

Updated · Methodology

Mechanism

Prolongation of the heart-rate-corrected QT interval (QTc), ventricular arrhythmias and sudden death have been reported with haloperidol, and the risk of QTc prolongation rises with the haloperidol dose and blood level (haloperidol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone SmPC, AEMPS). The Spanish domperidone SmPC lists haloperidol among the contraindicated antipsychotics because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation (AEMPS). Haloperidol metabolism involves glucuronidation, ketone reduction and the enzymes CYP3A4 and, to a lesser extent, CYP2D6. Haloperidol itself inhibits CYP2D6 (haloperidol SmPC, AEMPS). In the liver, CYP3A4 is the main enzyme that metabolises domperidone (domperidone SmPC, AEMPS), and the documents give no data on either drug changing the level of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Haloperidol adverse reactions include QT prolongation on the ECG, ventricular fibrillation, ventricular tachycardia, torsade de pointes and sudden death, as well as fast heart rate and low blood pressure, including when standing up (haloperidol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). Low potassium and magnesium raise the risk of ventricular arrhythmias (haloperidol SmPC, AEMPS), and according to the domperidone SmPC high potassium and a slow heart rate raise the risk of arrhythmia too (AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names haloperidol among these antipsychotics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish haloperidol SmPC also contraindicates haloperidol with all drugs that prolong the heart-rate-corrected QT interval (QTc), and its list of examples is not exhaustive. According to its own SmPC, domperidone is associated with QT prolongation (haloperidol and domperidone SmPCs, AEMPS). The US haloperidol label advises only particular caution with QT-prolonging drugs (haloperidol label, US Food and Drug Administration, FDA), so the Spanish SmPCs are stricter. Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (AEMPS), and haloperidol in a history of QTc prolongation or ventricular arrhythmias, congenital long QT syndrome, recent myocardial infarction, decompensated heart failure and uncorrected low potassium (haloperidol SmPC, AEMPS). Correct low potassium and magnesium before starting haloperidol and monitor electrolytes periodically afterwards. The SmPC also recommends a baseline electrocardiogram, a dose reduction if QTc lengthens and stopping haloperidol if QTc exceeds 500 ms (haloperidol SmPC, AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day and usually for no longer than one week, and stop it if signs of arrhythmia appear (domperidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Haloperidol